经济观察报·2025-08-12 11:05Core Viewpoint - The arbitration initiated by AestheFill against *ST Suwu is not unexpected, as the latter claims to be in a life-and-death situation due to the dispute over the exclusive agency rights for the AestheFill product [2][3]. Group 1: Arbitration and Legal Dispute - *ST Suwu's subsidiary, Datou Medical Devices (Shanghai) Co., Ltd., has applied for arbitration with the Shenzhen International Arbitration Court, seeking confirmation of its exclusive agency rights for AestheFill and continued supply from REGEN [2][3]. - Datou claims that if its exclusive agency rights are not confirmed, it will demand compensation of 1.6 billion yuan from REGEN, with the right to adjust this amount [2][3]. - AestheFill's agency rights dispute began in July 2025, with *ST Suwu having invested over 400 million yuan in clinical registration and market expansion for AestheFill [3]. Group 2: Financial Performance and Market Impact - In 2024, AestheFill was approved for sale in China, contributing to *ST Suwu's revenue of 330 million yuan, a more than 40-fold increase from the previous year, accounting for 21% of total revenue [3]. - The net profit for *ST Suwu, excluding non-recurring items, was 51.27 million yuan in 2024, marking its first positive figure in six years [3]. Group 3: Regulatory Issues and Company Actions - The China Securities Regulatory Commission (CSRC) found *ST Suwu guilty of multiple violations, including failing to disclose the actual controller and inflating revenue by 1.771 billion yuan over four years, resulting in a fine of 10 million yuan [4]. - On July 18, 2025, REGEN unilaterally terminated the exclusive agency agreement with Datou, citing violations of the agreement and the negative impact of *ST Suwu's regulatory issues on AestheFill's reputation [4]. Group 4: Market Reactions - As of August 12, *ST Suwu's stock was trading at 1.08 yuan per share, up 0.9%, with a total market capitalization of 768 million yuan; AestheFill's stock was at 188.45 yuan per share, up 0.72%, with a market cap of 57 billion yuan [5].